What should investors do with this diagnostic play as COVID cases drop?
Krsnaa Diagnostics presents superior contract execution and scalability in radiology diagnostics
PRO Only Highlights
– Quarterly performance largely backed by improved realisations
– Medium-term triggers China plus and protectionist measures for tyre industry
– Valuations not inexpensive; but improved medium-term outlook
When Krsnaa Diagnostics (Stock price: Rs 748; Market cap: Rs 2,347 crore) came out with an IPO in August this year, the second wave of the pandemic was haunting the country and infected people were thronging diagnostic labs to get a Covid test done. This helped the Krsnaa Diagnostics IPO to post a listing gain of 7.4 per cent. Since then Covid cases have shown a decline and the Krsnaa stock has underperformed broader markets. It is now trading 22…